Martin L Sos - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Martin L Sos

Showing results (31-40 of 60) with videos related to

Pageof 6

Sort By:

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2022

Report of the First International Symposium on NUT CarcinomaChristopher A French, Michael L Cheng, Glenn J Hanna, et al.

Proceedings of the National Academy of Sciences of the United States of America|October 5, 2012

A framework for identification of actionable cancer genome dependencies in small cell lung cancerMartin L Sos, Felix Dietlein, Martin Peifer, et al.

Journal of Medicinal Chemistry|August 15, 2015

Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design ApproachJulian Engel, André Richters, Matthäus Getlik, et al.

Nature Communications|April 11, 2026

Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapyJana Samarin, Hana Nůsková, Piotr Fabrowski, et al.

Journal of Medicinal Chemistry|April 29, 2022

Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing InhibitorsJonas Lategahn, Hannah L Tumbrink, Carsten Schultz-Fademrecht, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2013

Characteristics of lung cancers harboring NRAS mutationsKadoaki Ohashi, Lecia V Sequist, Maria E Arcila, et al.

The EMBO Journal|August 23, 2012

AATF/Che-1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosisKatja Höpker, Henning Hagmann, Safiya Khurshid, et al.

Nature Medicine|October 11, 2011

A crucial requirement for Hedgehog signaling in small cell lung cancerKwon-Sik Park, Luciano G Martelotto, Martin Peifer, et al.

European Journal of Cancer (Oxford, England : 1990)|December 15, 2022

Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitorsRichard Riedel, Jana Fassunke, Hannah L Tumbrink, et al.

Proceedings of the National Academy of Sciences of the United States of America|October 7, 2009

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancerMartin L Sos, Stefanie Fischer, Roland Ullrich, et al.

Pageof 6

Search research articles

Showing results (31-40 of 60) with videos related to

Sort By:

Pageof 6

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2022

Report of the First International Symposium on NUT CarcinomaChristopher A French, Michael L Cheng, Glenn J Hanna, et al.

Proceedings of the National Academy of Sciences of the United States of America|October 5, 2012

A framework for identification of actionable cancer genome dependencies in small cell lung cancerMartin L Sos, Felix Dietlein, Martin Peifer, et al.

Journal of Medicinal Chemistry|August 15, 2015

Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design ApproachJulian Engel, André Richters, Matthäus Getlik, et al.

Nature Communications|April 11, 2026

Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapyJana Samarin, Hana Nůsková, Piotr Fabrowski, et al.

Journal of Medicinal Chemistry|April 29, 2022

Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing InhibitorsJonas Lategahn, Hannah L Tumbrink, Carsten Schultz-Fademrecht, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2013

Characteristics of lung cancers harboring NRAS mutationsKadoaki Ohashi, Lecia V Sequist, Maria E Arcila, et al.

The EMBO Journal|August 23, 2012

AATF/Che-1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosisKatja Höpker, Henning Hagmann, Safiya Khurshid, et al.

Nature Medicine|October 11, 2011

A crucial requirement for Hedgehog signaling in small cell lung cancerKwon-Sik Park, Luciano G Martelotto, Martin Peifer, et al.

European Journal of Cancer (Oxford, England : 1990)|December 15, 2022

Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitorsRichard Riedel, Jana Fassunke, Hannah L Tumbrink, et al.

Proceedings of the National Academy of Sciences of the United States of America|October 7, 2009

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancerMartin L Sos, Stefanie Fischer, Roland Ullrich, et al.

Pageof 6